ACELYRIN, Inc.
SLRNDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962918
ACELYRIN, Inc. was delisted in 2025; its insiders filed their last Form 4 on May 23, 2025; 106 institutions reported holding it in 13F filings for Q1 2025, worth $182.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 106
- Q1 2025, −19 vs. previous quarter
- 13F value
- $182.7M
- Reported value at the end of Q1 2025
- Superinvestors holding
- 0
- At the end of Q1 2025
Superinvestors holding SLRN, Q1 2025
No superinvestor reported holding SLRN at the end of Q1 2025.
Latest insider trades
Open-market purchases and sales by ACELYRIN, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Kim MinaChief Executive Officer | SSale | −18.0K | $2.74 | −$49.3K | −2.6%671.8K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Murugan AmarChief Legal Officer | SSale | −3.91K | $2.74 | −$10.7K | −3.1%121.6K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Mpofu ShephardChief Medical Officer | SSale | −3.21K | $2.74 | −$8.80K | −2.6%121.8K after | |
| Jul 19, 2024 (view filing) | Jul 17 | 2 days | Becker Daniel J.Director | SSale | −1 | $6.86 | −$6.86 | 0.0%3.00K after | |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Lin Shao-LeeChief Executive Officer | SSale | −9.96K | $6.63 | −$66.0K | −0.6%1.58M after | |
| Feb 22, 2024 (view filing) | Feb 20 | 2 days | Lin Shao-LeeChief Executive Officer | SSale | −15.7K | $7.60 | −$119.3K | −1.0%1.59M after | |
| Jan 4, 2024 (view filing) | Jan 2 | 2 days | Lin Shao-LeeChief Executive Officer | SSale | −10.7K | $7.41 | −$79.2K | −0.7%1.60M after | |
| May 11, 2023 (view filing)9:16 PM ET | May 9 | 2 days | Harper Sean E and 2 others10% Owner | PPurchase | +1.25M | $18.00 | +$22.5M | +14.6%9.79M after | Duplicate filing |
| May 11, 2023 (view filing) | May 9 | 2 days | Seidenberg Beth CDirector, 10% Owner | PPurchase | +1.25M | $18.00 | +$22.5M | +14.6%9.79M after | |
| May 11, 2023 (view filing) | May 9 | 2 days | Seidenberg Beth CDirector, 10% Owner | PPurchase | +60.0K | $18.00 | +$1.08M | New position60.0K after |
Top 10 13F holders, Q1 2025
The largest institutional positions in ACELYRIN, Inc. at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 9,818,115 | $24.3M | 1.34% | +9,818,115 | New |
| AyurMaya Capital Management Company, LP | 9,334,735 | $23.1M | 26.08% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,805,096 | $14.3M | 0.00% | −215,772−3.6% | Reduced |
| T. Rowe Price Investment Management, Inc. | 4,649,865 | $11.5M | 0.01% | −8,222,259−63.9% | Reduced |
| Madison Avenue Partners, LP | 4,142,640 | $10.2M | 0.87% | +4,142,640 | New |
| Vanguard Group Inc | 4,079,706 | $10.1M | 0.00% | −3040.0% | Reduced |
| OrbiMed Advisors LLC | 4,001,711 | $9.88M | 0.24% | 00.0% | Unchanged |
| venBio Partners LLC | 3,806,410 | $9.40M | 7.61% | 00.0% | Unchanged |
| Velan Capital Investment Management LP | 3,366,945 | $8.32M | 8.56% | +3,366,945 | New |
| Tybourne Capital Management (HK) Ltd | 2,906,629 | $7.18M | 30.48% | 00.0% | Unchanged |